Senate File 85 creates a new “health equity program” within the Iowa Department of Health and Human Services to reimburse the cost of covered services, treatments, supplies, and drugs related to menstrual and post-menstrual health conditions when those costs are not otherwise covered by a third-party payer. The bill is aimed at conditions such as periods, fibroids, endometriosis, perimenopause, menopause, incontinence, atrophic vaginitis, and other hormone-related conditions, and it specifically contemplates services such as hormone treatments, urinary tract treatments, vaginal estrogens, nerve therapies, and related care. The department would be required to adopt rules, promote the program statewide, and keep administrative costs at or below 4% of annual appropriations.
The bill also creates a dedicated health equity program fund in the state treasury. Money in the fund would come from legislative appropriations and could also include federal or private funds, and unused balances would not revert to the general fund at the end of the fiscal year. The bill directs that reimbursement be paid directly to participating providers within 10 days of a billing statement, subject to eligibility and available funds, and it makes the program a payor of last resort. Providers would need to be in good standing with their licensing board, and claims would be limited to actual provider costs.
In addition to establishing the program, the bill makes a one-time appropriation to the fund equal to the total state revenue previously spent on genitourinary agents for state employees under the public employee group insurance plan from July 1, 2002, through June 30, 2022. It also requires annual reporting to the governor and the legislature on the fund balance, participating providers, billed amounts, services reimbursed, and recommended changes. The bill would therefore add a new statutory section to chapter 135 and could be codified as a new subchapter titled the Health Equity Program and Fund.
The overall sentiment reflected in the available context is limited because there are no recorded committee transcripts or votes, but the bill’s structure suggests a policy-focused effort to expand access to care for menstrual and post-menstrual health needs. The measure appears designed to address gaps in insurance coverage and to create a targeted reimbursement mechanism for patients and providers. At the same time, the bill includes fiscal controls, such as the 4% administrative cap, payor-of-last-resort language, and a waiting list if funds are insufficient, indicating attention to cost containment and program administration.
The main points of potential contention are likely to be the scope of covered treatments, the use of state funds for what some may view as specialized or controversial reproductive and hormone-related care, and the size and source of the initial appropriation. Questions may also arise about whether the program duplicates private insurance coverage, how broadly provider discretion should be allowed, and whether the reimbursement structure is sufficiently limited to prevent open-ended state liability. Because there is no recorded debate or vote history in the provided materials, these concerns are inferred from the bill’s design rather than from documented opposition.
SF 85 would add a new section to Iowa Code chapter 135 establishing a state-run reimbursement program for menstrual and post-menstrual health care and creating a dedicated fund for that purpose. It would require the Department of Health and Human Services to administer the program by rule, reimburse participating providers for eligible services not covered by insurance or other third-party payors, and report annually to the governor and legislature. The bill also creates a standing appropriation structure, prevents year-end reversion of unused funds, and directs a one-time transfer based on historical state spending on genitourinary agents for public employees, thereby affecting state budgeting, health program administration, and provider reimbursement practices.
The available record shows no committee transcript and no votes, so there is no documented floor or committee sentiment to summarize directly. Based on the bill text, the measure appears to be framed as a health equity and access initiative, with a strong emphasis on expanding treatment options for menstrual and post-menstrual conditions. The inclusion of administrative cost limits, reimbursement controls, and annual reporting suggests an effort to make the proposal more fiscally defensible and administratively structured.
Likely areas of contention include whether the state should fund a dedicated program for menstrual and post-menstrual health, how broad the list of covered services should be, and whether the bill’s reimbursement mechanism could overlap with or substitute for private insurance coverage. The one-time appropriation tied to prior state spending on genitourinary agents may also draw scrutiny over cost and precedent. Supporters would likely emphasize access to care, health equity, and coverage gaps, while skeptics may focus on fiscal exposure, program scope, and the use of public funds for treatments that some may consider outside core state health obligations.